CEDAR KNOLLS, N.J.,
June 6, 2018 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and the
owner of Fortetropin®, a proprietary bioactive composition derived
from fertilized egg yolk that helps build lean muscle, today
announced the launch of 'MYOS Canine Muscle
Formula'. This is the first product in the Company's
new line of advanced veterinary health supplements to support
muscle health in dogs, featuring Fortetropin® as the active
ingredient.
Joseph Mannello, Chief Executive
Officer of the Company, stated, "We are excited to be launching our
first veterinary health supplement, which helps support muscle
health in dogs. Over the last year, Fortetropin® consumers reached
out to tell us about their personal experiences using our products
and their observations of their dogs who consumed
Fortetropin®. As often happens, people share what's good for
them with their pets and these consumers stated that their dogs
showed noticeable improvement in their energy and physical
abilities after consuming Fortetropin®. We then took it a
step further and tested Fortetropin® products with veterinarians,
who reported that older dogs engaged in more physical activity
after consuming Fortetropin®, and resumed certain activities that
were thought to have stopped because of age. We plan to distribute
this supplement through established veterinary practices throughout
the country offering customers a home delivery auto-ship
option."
"As we've stated in prior announcements and conference calls, we
view the veterinary supplement market as an untapped growth
opportunity for the Company. According to a report from Packaged
Facts, Pet Supplements in the U.S., 6th Edition, U.S. sales
of veterinary supplements reached $580
million in 2016, up 3.5% from the previous year."
There are 57 million pet owners in the 18 to 39 year-old range who
are more likely to depend on their veterinarians for advice about
pet products.
The supplement comes in powder form and is available for dogs of
all sizes. MYOS Canine Muscle Formula is formulated
to mix well with and fortify a dog's existing food of choice. A
single canister provides approximately 60 servings/two-month supply
of product for a medium-sized dog.
"To the best of our knowledge, there is no pet health supplement
product that addresses muscle atrophy," continued Mr. Mannello.
"The feedback we have received from veterinarians and pet owners
has been overwhelmingly positive. Given that lean muscle mass is
inversely associated with mortality from all causes in humans, we
believe veterinarians, as well as consumers, will appreciate the
muscle-enhancing benefits of adding Fortetropin® to their
dog's diet. Please contact us for further information or to
purchase the product: MYOS RENS Technology, 973-509-0444;
www.myospet.com.
"Our commitment to the science behind Fortetropin® along with
the potential of developing a veterinary product line, led us to
launch a clinical study at Kansas State
University in 2017 to determine if daily supplementation of
Fortetropin® is effective in reducing muscle atrophy in dogs that
undergo TPLO surgery (which is comparable to ACL surgery in
humans). The study is nearly complete and we expect to announce the
results before the end of 2018."
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company
that develops and markets products that improve muscle health and
performance. MYOS is the owner of Fortetropin®, a fertilized egg
yolk-based product manufactured via a proprietary process to retain
and optimize its biological activity. Fortetropin® has been
clinically shown to increase muscle size and lean body mass in
conjunction with resistance training. MYOS believes Fortetropin®
has the potential to redefine existing standards of physical health
and wellness. For more information, please visit
www.MYOSRENS.com.
Forward-Looking Statements
Any statements
in this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, including the products described
herein, the ability to create new products through research and
development, including the products described herein, the
successful results of strategic initiatives, the successful launch
of our products, including Qurr® products and the
products described herein, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, including the results of
the study described herein, the ability to enter into new
partnership opportunities and the success of our existing
partnerships, the ability to generate the forecasted revenue stream
and cash flow from sales of our products, the ability to continue
increasing our revenue and gross profit margins, the ability to
achieve a sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-launches-advanced-veterinary-supplement-product-for-dogs-powered-by-fortetropin-300660460.html
SOURCE MYOS RENS Technology Inc.